G Ganesh, C Shertaeva, G Umurzakhova, M Sapakbay, S Seidaliyeva
Digitalization is becoming a key factor in increasing the competitiveness of the pharmaceutical industry. The experience of pharmaceutical companies demonstrates that effective digital transformation must combine technological innovation, data analysis, engagement with the medical community, and a focus on patient needs. Further development of the industry requires investment in AI, Big Data, digital infrastructure, personnel training, and improved regulatory frameworks.
AIM: To examine the key areas and main directions of digital transformation in the pharmaceutical industry, with a focus on Kazakhstan, and identify opportunities, barriers and adaptation strategies for pharmaceutical companies to adapt to new technological realities.
MATERIALS AND METHODS: A narrative analytical review based on secondary data analysis was conducted. Scientific publications, official regulatory documents, state digitalisation materials, market reports, company publications, and industry media sources were analysed. Sources were selected using predefined keywords related to pharmaceutical digitalisation, artificial intelligence, Big Data, e-commerce, drug labelling, traceability, logistics, digital communication, and Kazakhstan's pharmaceutical sector. The selected materials were analysed thematically.
RESULTS: Digitalisation in the pharmaceutical industry includes automation of production processes, artificial intelligence and machine learning, Big Data analytics, e-commerce, digital communication with healthcare professionals and patients, medicine labelling and traceability, and logistics digitalisation. In Kazakhstan, digital transformation is reflected in the development of online pharmacy services, implementation of mandatory medicine labelling, digitalisation of SK-Pharmacy logistics, and the use of Big Data technologies in pharmacy organizations. Kazakhstan-based data show that 97.2% of surveyed pharmacy organizations use basic automation tools, while comprehensive information-analytical systems are implemented in only 23.7%.
CONCLUSION: Digitalization is becoming a key factor in increasing the competitiveness of the pharmaceutical industry. The experience of pharmaceutical companies demonstrates that effective digital transformation must combine technological innovation, data analysis, engagement with the medical community, and a focus on patient needs. Further development of the industry requires investment in AI, Big Data, digital infrastructure, personnel training, and improved regulatory frameworks.